Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
EXINA On Other Exchanges
EXINA is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

exini diagnostics ab-a shs (EXINA) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

exini diagnostics ab-a shs (EXINA) Related Businessweek News

No Related Businessweek News Found

exini diagnostics ab-a shs (EXINA) Details

EXINI Diagnostics AB (publ) provides software products for medical decision support in Sweden and internationally. It offers various software products, including EXINI bone for diagnosing prostate cancer and analyzing bone scintigraphy; EXINI heart, which provides analysis of myocardial perfusion scintigraphy; EXINI brain for diagnosing dementia by processing cerebral blood flow scans; and EXINI dat for diagnosing parkinsonian syndromes using quantification of striatal uptake. The company was founded in 1999 and is based in Lund, Sweden.

Founded in 1999

exini diagnostics ab-a shs (EXINA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

exini diagnostics ab-a shs (EXINA) Key Developments

EXINI Upgrades Agreement with FUJIFILM RI Pharma to Develop Version 2.0 of the Software EXINI Heart

EXINI and FUJIFILM RI Pharma have agreed to develop version 2.0 of the software EXINI heart (cardioREPO) in collaboration with renowned Japanese university hospitals. EXINI heart was launched onto the Japanese market a year ago and is currently used in well over 500 hospitals throughout Japan. EXINI will be managing the project in close collaboration with FUJIFILM RI Pharma and well-known Japanese university hospitals. The objective is to further enhance the artificial intelligence and other important features of the software. The collaboration combines EXINI's deep knowledge in machine learning and clinical databases with FUJIFILM RI Pharma's application expertise and close contact with end users. The project will be funded by FUJIFILM RI Pharma and is expected to last 14 months.

EXINI Diagnostics AB (publ), Annual General Meeting, Apr 27, 2015

EXINI Diagnostics AB (publ), Annual General Meeting, Apr 27, 2015.

EXINI Announces Board Changes

EXINI board member, Henrik Perlmutter, has been appointed as Chairman of the Board of EXINI Diagnostics AB (publ) until the forthcoming General Meeting on April 27 due to the sick leave of Fredrik Lindgren. Henrik Perlmutter has served as a member of the board since 2011 and has over 40 years of experience from the life science industry.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXINA:SS kr0.00 SEK 0.00

EXINA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EXINA.
View Industry Companies

Industry Analysis


Industry Average

Valuation EXINA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXINI DIAGNOSTICS AB-A SHS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at